It is widely recognized that poor oral health can affect overall health and that untreated caries can become life-threatening. Nearly 80% of all patients have signs of early caries, and the majority will leave the dental office without treatment, risking more serious disease. Curodont Repair Fluoride Plus empowers dental practices to address this untapped opportunity, expanding patient care with a noninvasive approach. 

Stanley M. Bergman, chairman of the board and CEO of Henry Schein, commented in a press release: “We believe that Curodont advances clinical care by treating early decay before it worsens. With this treatment, the dental team can treat early-stage caries noninvasively and on the same day instead of sending patients home untreated. Henry Schein is pleased to bring products to market that improve clinical outcomes, including Curodont Repair Fluoride Plus, while helping practices operate more efficiently and effectively by advancing oral health and overall health for the ultimate benefit of the patient.” 

The partnership between Henry Schein and vVARDIS builds on other innovations that support the early treatment of oral disease. In late 2022, Henry Schein One introduced Dentrix Detect AI, an artificial intelligence-enabled radiograph analysis tool developed by VideaHealth. The tool provides real-time clinical decision support and can detect incipient carious lesions more accurately than the naked eye, expanding the patient population that could benefit from the use of Curodont Repair Fluoride Plus. Dental professionals who use Dentrix Detect AI and Curodont Repair Fluoride Plus in concert may be able to treat early carious lesions more effectively before greater disease progression occurs. 

Henry Schein is the market leader in sales of Curodont Repair Fluoride Plus to dentists and DSOs. With this agreement, Henry Schein will have the exclusive rights to distribute Curodont Repair Fluoride Plus to larger DSOs, a market segment driving significant growth. The company will continue to distribute Curodont products to other segments of the market and in other markets outside of North America as product registrations are obtained. The terms of the agreement were not disclosed. 

“We are excited to strengthen our partnership with Henry Schein, a recognized leader in driving technological innovation in dentistry,” Drs. Haleh and Golnar Abivardi, the founders and co-CEOs of vVARDIS, wrote in the press release. They continued: “Henry Schein’s global reach makes for an ideal partner, as we share a common goal: advancing oral health by providing access to innovative, noninvasive solutions. Through this partnership, almost every patient can now benefit from Curodont. As both dentists and entrepreneurs, we are thrilled to finally have and offer a novel approach to treating early decay. Dental professionals have been waiting for decades for a drill-free treatment that addresses the subclinical signs of caries immediately, without sending patients home untreated and compromising their overall health. With its seamless integration into existing workflows, we believe that Curodont has the potential to rapidly become the new standard of care for the treatment of early caries, broadening the scope of services offered and empowering dentists and hygienists to lead the way in the management of early caries, ultimately enhancing patient care.” 

Tags: